We are on a mission to elevate patient care in breast cancer and beyond.
With nearly 2 million new diagnoses annually, breast cancer is the second most prevalent cancer worldwide. Up to 30% of people diagnosed with breast cancer ultimately develop metastatic disease.
Like many people and families, much of our team has been personally affected by this disease, fueling our collective passion to create more effective, safe, and convenient treatments to help people living with cancer feel better, longer. Meet our team of oncology experts with a track record of bringing disruptive new therapies to market.
Our Team
leadership
board of directors
leadership
board of directors
leadership
Sean P. Bohen, M.D., Ph.D.
President and CEO
Shane Kovacs
Chief Operating and Financial Officer
Naseem Zojwalla, M.D.
Chief Medical Officer
David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Julie Dexter
Senior Vice President and Head of People
Sasha Austin, CPA
Vice President, Finance and Controller
Yolande Du Toit, MD
Vice President, Medical Affairs
Richard Hernandez
Vice President, Clinical Development Operations
Kamesh Kuchimanchi, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
Kristin Lanzi
Vice President, Information Technology
Courtney O'Konek
Vice President, Corporate Communications
Gopinath Palanisamy, DVM, Ph.D., DACVP
Vice President, Pre-Clinical Pharmacology and Toxicology
Mark Shilkrut, M.D., Ph.D.
Vice President, Clinical Development
Kate Swearingen
Vice President, Program Management
Margaret Tonda, PharmD
Vice President, Clinical Science
Rachel Wei, Ph.D.
Vice President, Biostatistics
Jim Zhang, Ph.D.
Vice President, CMC
Sean P. Bohen, M.D., Ph.D.
President and CEO
Ian Clark
Chairman of the Board
Cindy Butitta
Member
Scott Garland
Member
Cyrus Harmon, Ph.D.
Member
Sandra J. Horning, M.D., FACP, FASCO
Member
Gorjan Hrustanovic, Ph.D.
Member
Yi Larson, MBA
Member
Andy Rappaport
Member
Graham Walmsley, M.D., Ph.D.
Member